Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Conference Highlights ASCO
Melanoma
,
Conference Highlights ASCO
Novel LAG-3–Blocking Antibody plus Nivolumab Shows Promise as First-Line Treatment in Advanced Melanoma
Wayne Kuznar
Wayne Kuznar
Read More
FDA Approvals
,
Urothelial Cancer
,
Conference Highlights ASCO
Padcev Receives Regular FDA Approval for Locally Advanced or Metastatic Urothelial Cancer
Read More
FDA Approvals
,
Conference Highlights ASCO
Pembrolizumab plus Lenvatinib Combination Receives Regular Approval for Advanced Endometrial Carcinoma
Read More
Value-Based Care
,
Conference Highlights ASCO
Rapid Biosimilar Adoption Possible in Community Oncology Practice
Chase Doyle
Chase Doyle
Read More
FDA Approvals
,
Leukemia
,
Lymphoma
,
Conference Highlights ASCO
Rylaze FDA Approved as Part of a Treatment Regimen for Pediatric Leukemia and Lymphoma
Read More
Cholangiocarcinoma
,
FDA Approvals
,
Conference Highlights ASCO
Truseltiq Second Targeted Therapy Approved for Metastatic Cholangiocarcinoma Harboring FGFR2 Alterations
Read More
Prostate Cancer
,
Conference Highlights ASCO
¹⁷⁷Lu-PSMA-617 Prolongs Survival in Patients with Metastatic Castration-Resistant Prostate Cancer
Phoebe Starr
Phoebe Starr
Read More
Conference Highlights ASCO
Precision Medicine and Immunotherapy Highlighted at ASCO 2018
Wayne Kuznar
Read More
1
2
Page 2 of 2
Results 11 - 18 of 18